Growth hormones can be misused by athletes both in and out of competition to gain an unfair advantage by enhancing physiological processes that may improve athletic performance. As a result, laboratories routinely analyze prohibited compounds to support anti-doping efforts and ensure fair play in sport. Sensitive and reproducible analytical methods are therefore required for their detection in biological samples.
Accurate analysis of these compounds in urine can be challenging due to their diverse chemical properties, low target concentrations, and the potential for matrix effects. Efficient sample preparation is therefore important for achieving reproducible analyte recovery and clean extracts while supporting high-throughput laboratory workflows.
This application note describes the extraction of a panel of basic peptide hormones, synthetic analogues, and growth hormone secretagogues from human urine using EVOLUTE® EXPRESS WCX solid phase extraction plates prior to LC-HRMS analysis. The sample preparation method was evaluated using both manual and automated processing. Manual sample preparation was performed using the Biotage® Pressure+ 96 positive pressure manifold, while automated sample preparation was performed using the Biotage® Extrahera™ Classic. An optimized load-wash-elute protocol streamlined sample preparation and enabled the processing of 96 samples in approximately 40 minutes. See appendix for automation parameters.
The automated method provided recoveries of 61-97%, RSDs below 5%, and matrix factors of 0.93-1.02. Estimated LOQs were 0.2 ng/mL or lower for most analytes and 1 ng/mL or lower for all analytes.
Alexamorelin, anamorelin, buserelin, capromorelin, deslorelin, gonadorelin, goserelin, histrelin, ibutamoren (MK-677), leuprorelin (leuprolide), macimorelin, nafarelin, tabimorelin, triptorelin. Gonadorelin and triptorelin were selected as representative examples of the peptide analytes included in this application note. Their structures illustrate the shared peptide backbone and the structural modifications that can influence analyte behavior during sample preparation (Figure 1).
EVOLUTE® EXPRESS WCX 30 mg plate, part number 602-0030-PX01
Add 100 µL MeCN to 500 µL of human urine in a 2mL 96-well collection plate. Further dilute samples with 500 µL 50 mM ammonium acetate, pH 8 (aq), to give a total sample volume of 1.1 mL.
The spiking solution consisted of a 100 ng/mL solution in 50% methanol (aq). 10 µL was added to 500 µL of urine to give a spike concentration of 2 ng/mL.
Condition each well with 1 mL MeOH.
Equilibrate each well with 1 mL of 50mM ammonium acetate buffer, pH 8 (aq).
Load 1 mL of the pre-treated urine into each well.
Elute interferences with 1 mL of 50mM ammonium acetate buffer, pH 8 (aq).
Elute interferences with 1 mL of H2O:MeCN (70:30, v/v).
Dry the sorbent bed for approximately 5 minutes.
Elute the analytes with 500 µL of 5% formic acid in MeCN:H2O (90:10, v/v).
Evaporate the extracts to dryness under a stream of nitrogen using a Biotage® TurboVap® 96 Dual.
Table 1. TurboVap® 96 Dual settings.
|
TurboVap® 96 Dual settings |
|
|
Gas temperature |
40 °C |
|
Plate temperature |
40 °C |
|
Flow rate |
60 L/min |
|
Plate height |
48 mm |
|
Time |
35 minutes, or until dryness |
Reconstitute the dried sample extracts in 200 µL of 0.3% formic acid in H2O:MeCN (75:25, v/v), cover the collection plate with a sealing mat. Sufficiently vortex-mix prior to injection.
Thermo Scientific Dionex Ultimate 3000
Waters XSelect® CSH™ C18 2.5 µm (50 mm x 3.0 mm) (p/n 186006105) with a XSelect CSH C18 2.5 µm XP VanGuard® (5 mm x 2.1 mm) (p/n 186007817) cartridge
Mobile phase A: 0.3% formic acid and 1% DMSO in H2O
Mobile phase B: 0.3% formic acid and 1% DMSO in MeCN
0.4 mL/min
10 µL
30 °C
10 °C
Table 2. UHPLC gradient conditions.
|
Time (min) |
%A |
%B |
|
0.00 |
98 |
2 |
|
6.00 |
5 |
95 |
|
8.00 |
5 |
95 |
|
8.01 |
98 |
2 |
|
12.00 |
98 |
2 |
Instrument
Thermo Scientific Q Exactive Focus
Settings
Sheath gas flow rate: 30
Aux gas flow rate: 5
Sweep gas flow rate: 0
Spray voltage: 4 kV
Capillary temperature : 320 °C
S-lens RF level: 50
Aux gas heater temperature: 400°C
Table 3. HRMS Conditions for target analytes in positive ion mode, resolution 35,000.
|
Analytes |
Monoisotopic mass (Da) |
Main charge state |
Exact mass |
|
Gonadorelin |
1181.57 |
[M+2H]2+ |
591.79 |
|
Alexamorelin |
957.50 |
[M+2H]2+ |
479.75 |
|
Histrelin |
1322.67 |
[M+2H]2+ |
662.34 |
|
Goserelin |
1268.64 |
[M+2H]2+ |
635.32 |
|
Leuprorelin (Leuprolide) |
1208.65 |
[M+2H]2+ |
605.33 |
|
Triptorelin |
1310.63 |
[M+2H]2+ |
656.32 |
|
Buserelin |
1238.66 |
[M+2H]2+ |
620.33 |
|
Macimorelin |
474.24 |
[M+H]+ |
475.24 |
|
Deslorelin |
1281.64 |
[M+2H]2+ |
641.82 |
|
Nafarelin |
1321.64 |
[M+2H]2+ |
661.82 |
|
Capromorelin |
505.27 |
[M+H]+ |
506.27 |
|
Ibutamoren (MK-677) |
528.24 |
[M+H]+ |
529.24 |
|
Tabimorelin |
528.31 |
[M+H]+ |
529.31 |
|
Anamorelin |
546.33 |
[M+H]+ |
547.34 |
Manual extraction resulted in high, reproducible recoveries (Figure 3) ranging from 67-95% with corresponding RSDs <6% (Figure 4). Good matrix removal was demonstrated by low ion suppression detected, with matrix factors ranging from 0.88-0.96 (Figure 5). Optimization of the pretreatment buffer pH resulted in improved recovery for all analytes compared with the unmodified buffer.
Removal of the conditioning and equilibration step had no effect on overall recovery (Figure 2), matrix factors or reproducibility. Based on these results, a simplified load-wash-elute (L-W-E) workflow was used, removing the need for conditioning and equilibration steps. This provided additional time and cost benefits, particularly when processing larger sample batches. When processing 96 samples on the Biotage® Extrahera™ Classic, the L-W-E protocol reduced processing time by 10 minutes, from approximately 50 minutes to 40 minutes.
Figure 2. Analyte recoveries (2 ng/mL in urine) using the optimized load-wash-elute EVOLUTE® EXPRESS WCX 30mg protocol compared to a full protocol using conditioning and equilibration, both performed manually using a Biotage® PRESSURE+ 96.
An automated extraction on the Biotage® Extrahera™ Classic achieved reproducible recoveries ranging from 61-97% (Figure 3) and RSDs <5% (Figure 4). Low ion suppression was demonstrated with matrix factors ranging from 0.93-1.02 (Figure 5). The automated method delivered slightly lower recoveries when compared to the manual method. This may be due to non-specific binding of the analytes to the sample plate prior to processing, resulting from the increased residence time before loading onto the SPE plate. Addition of 100 µL MeCN to the samples in the sample plate improved recoveries by improving analyte solubility in the urine samples.
Figure 3. Analyte recoveries (2 ng/mL in urine) using the optimized load-wash-elute EVOLUTE® EXPRESS WCX 30mg protocol. Recovery data comparing manual and automated processing is shown.
Figure 4. Analyte RSDs (2 ng/mL in urine) using the optimized load-wash-elute EVOLUTE® EXPRESS WCX 30mg protocol. Reproducibility data comparing manual and automated processing is shown.
Figure 5. Analyte matrix factors (2 ng/mL in urine) using the optimized load-wash-elute EVOLUTE® EXPRESS WCX 30mg protocol. Matrix factor data comparing manual and automated processing is shown.
Good linearity was observed for all analytes over the ranges detailed in Table 4, with R2 values typically greater than 0.99. LOQ values were estimated based on a signal to noise ratio (S/N) of 10 to 1, a representative chromatogram can be found in Figure 6.
Figure 6. Representative chromatogram for panel spiked in reconstitution solvent at 2ng/mL.
Table 4. Analyte calibration curve (R2) and LOQ performance for the manual and automated methods.
|
|
Manual |
Automated |
||||
|
Analyte |
Range (ng/mL) |
R2 |
LOQ (ng/mL) |
Range (ng/mL) |
R2 |
LOQ (ng/mL) |
|
Gonadorelin |
0.05-5 |
0.996 |
0.05 |
0.05-5 |
0.992 |
0.1 |
|
Alexamorelin |
0.05-5 |
0.990 |
0.1 |
0.05-5 |
0.993 |
0.2 |
|
Histrelin |
0.05-5 |
0.996 |
0.05 |
0.05-5 |
0.997 |
0.05 |
|
Goserelin |
0.05-5 |
0.996 |
0.1 |
0.05-5 |
0.995 |
0.2 |
|
Leuprorelin |
0.05-5 |
0.997 |
0.1 |
0.2-5 |
0.991 |
0.2 |
|
Triptorelin |
0.05-5 |
0.996 |
0.1 |
0.05-5 |
0.993 |
0.2 |
|
Buserelin |
0.05-5 |
0.996 |
0.2 |
0.2-5 |
0.996 |
0.5 |
|
Macimorelin |
0.05-5 |
0.996 |
0.2 |
0.5-5 |
0.997 |
1 |
|
Deslorelin |
0.05-5 |
0.994 |
0.1 |
0.05-5 |
0.997 |
0.05 |
|
Nafarelin |
0.1-5 |
0.997 |
0.1 |
0.2-5 |
0.995 |
0.5 |
|
Capromorelin |
0.05-5 |
0.994 |
0.1 |
0.05-5 |
0.999 |
0.1 |
|
Ibutamoren |
0.05-5 |
0.996 |
<0.05 |
0.05-5 |
0.997 |
<0.05 |
|
Tabimorelin |
0.1-5 |
0.996 |
0.1 |
0.2-5 |
0.994 |
0.5 |
|
Anamorelin |
0.05-5 |
0.996 |
0.05 |
0.05-5 |
0.995 |
0.05 |
Figure 7. Calibration curves for Gonadorelin, Triptorelin, Deslorelin and Anamorelin using EVOLUTE® EXPRESS WCX 30 mg plate to extract from human urine, calibration range 0.05-5 ng/mL.
A solid phase extraction method was automated for a panel of basic peptides from urine using Biotage® EVOLUTE® EXPRESS WCX 30 mg 96-well plates. High, reproducible recoveries were obtained with an overall automated processing method time of approximately 40 minutes for 96 samples. An optimized method utilized the load-wash-elute protocol possible by using the polymeric resin, improving efficiency of the overall method. The automated sample preparation method achieved LOQs of 1 ng/mL or lower for all analytes, with most analytes achieving estimated LOQs of 0.2 ng/mL or lower.
LCMS Grade methanol, acetonitrile and formic acid were purchased from Rathburn (Walkerburn, UK).
Water used was 18.2 MΩhm-cm and was drawn daily from a Synergy® UV water purifier.
HPLC grade ammonium acetate was purchased from Honeywell Research Chemicals (Bucharest, Romania).
Anamorelin, Buserelin, Capromorelin, Deslorelin, Gonadorelin, Goserelin, Histrelin, Ibutamoren (MK-677), Leuprorelin (Leuprolide), Macimorelin, Nafarelin, and Triptorelin were purchased from Sigma-Aldrich Company LTD. (Gillingham, UK)
Alexamorelin was purchased from Cambridge Biosciences (Cambridge, UK).
Tabimorelin was purchased from LGC Standards (Teddington, UK).
Mobile phase A (0.3% formic acid and 1% DMSO in water) was prepared by adding 3 mL formic acid and 10 mL DMSO to 1 L purified water.
Mobile phase B (0.3% formic acid and 1% DMSO in acetonitrile) was prepared by adding 3 mL formic acid and 10 mL DMSO to 1 L LCMS grade acetonitrile.
Equilibration, Wash 1, and pretreatment buffer (50mM NH4OAc (pH 8) in water) was prepared by adding 3.854 g ammonium acetate to 1 L purified water and mix well. pH modified to pH 8 using ammonium hydroxide.
Wash 2 solvent (70:30 H2O:MeCN) was prepared by adding 700 mL purified water to 300 mL LCMS grade acetonitrile.
Elution solvent (5% formic acid in 90:10 MeCN: H2O) was prepared by adding 90 mL LC-MS- grade acetonitrile to 10 mL purified water. Then, 5 mL discarded and 5 mL LCMS grade formic acid added.
Reconstitution solvent was prepared by adding 75 mL purified water to 25 mL LCMS grade acetonitrile. Then, adding 300 µL LC-MS-grade formic acid.
Human urine was provided by healthy human volunteers.
Low-binding protein plastics were used at all possible stages during the development of the sample preparation method. Use of a low-binding protein 96-well collection plate could improve recoveries on the Biotage® Extrahera™ Classic, although this remains untested. Standard 2 mL collection plates supplied by Biotage were used in this development. Appendix available for download.
Literature number: AN1038